<DOC>
	<DOC>NCT03025360</DOC>
	<brief_summary>Larotrectinib (LOXO-101) expanded access is for patients with cancer with a NTRK1, NTRK2, or NTRK3 gene fusion who are ineligible for an ongoing larotrectinib (LOXO-101) clinical trial or have other considerations that prevent access to larotrectinib (LOXO-101) through an existing clinical trial. Expanded access is intended to treat individual patients with different types of cancers with a NTRK gene fusion.</brief_summary>
	<brief_title>Expanded Access to Provide Larotrectinib (LOXO-101) for the Treatment of Cancers With a NTRK Gene Fusion</brief_title>
	<detailed_description />
	<criteria>Diagnosis of cancer with a NTRK1, NTRK2, or NTRK3 gene fusion Are unable to participate in an ongoing larotrectinib (LOXO101) clinical trial Willing and able to provide written, signed informed consent Medically suitable for treatment with larotrectinib (LOXO101) Currently enrolled in an ongoing clinical study of larotrectinib (LOXO101) or another TRK inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>